The company is a biopharmaceutical firm that develops and commercializes small-molecule targeted cancer therapies, with a primary focus on chronic myeloid leukemia, myelodysplastic syndrome, and other blood cancers. It currently markets two approved products—Olverembatinib and Lisaftoclax—directly in China with reimbursement coverage through the Chinese National Reimbursement Drug List, and is conducting Phase 3 clinical trials in the United States and other international markets to pursue regulatory approvals. The company generates revenue from direct product sales in China, strategic partnerships and licensing arrangements, and manufactures its products through facilities in Suzhou and Taizhou with substantial manufacturing capacity, while competing against major pharmaceutical companies in the oncology space.